Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Citi
Fish and Richardson
Covington
Accenture
Boehringer Ingelheim

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,431,942

« Back to Dashboard

Which drugs does patent 7,431,942 protect, and when does it expire?

Patent 7,431,942 protects DEXILANT SOLUTAB and PREVACID and is included in two NDAs.

Protection for DEXILANT SOLUTAB has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty patent family members in sixteen countries.

Summary for Patent: 7,431,942
Title:Orally disintegrable tablets
Abstract:An orally disintegrable tablet of the present invention, which comprises (i) fine granules having an average particle diameter of 400 .mu.m or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration.
Inventor(s): Shimizu; Toshihiro (Itami, JP), Morimoto; Shuji (Suita, JP), Tabata; Tetsuro (Suita, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:10/017,755
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,431,942
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,431,942
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Compound;

Drugs Protected by US Patent 7,431,942

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa DEXILANT SOLUTAB dexlansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 208056-001 Jan 26, 2016 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Takeda Pharms Usa PREVACID lansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 021428-001 Aug 30, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Takeda Pharms Usa PREVACID lansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 021428-002 Aug 30, 2002 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,431,942

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan10-135472May 18, 1998
Japan10-219266Aug 03, 1998
Japan10-222151Aug 05, 1998
Japan11-005144Jan 12, 1999
Japan11-015851Jan 25, 1999

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Medtronic
Chinese Patent Office
Argus Health
US Army
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.